Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment
Tibor Štark, Serena Di Martino, Filippo Drago, et al.
Pharmacological Research (2021) Vol. 174, pp. 105938-105938
Closed Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders
Berhanu Geresu Kibret, Hiroki Ishiguro, Yasue Horiuchi, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 2, pp. 975-975
Open Access | Times Cited: 45
Cannabidiol: Bridge between Antioxidant Effect, Cellular Protection, and Cognitive and Physical Performance
George Jîtcă, Bianca Eugenia Ősz, Camil-Eugen Vari, et al.
Antioxidants (2023) Vol. 12, Iss. 2, pp. 485-485
Open Access | Times Cited: 24
Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson's disease and in comorbidity with psychiatric disorders
Maria de Fátima dos Santos Sampaio, Yara Bezerra de Paiva, Tuane Bazanella Sampaio, et al.
Basic & Clinical Pharmacology & Toxicology (2024) Vol. 134, Iss. 5, pp. 574-601
Open Access | Times Cited: 12
Tetrahydrocannabinol and cannabidiol medicines for chronic pain and mental health conditions
Jeremy D. Henson, Luis Vitetta, Sean Hall
Inflammopharmacology (2022) Vol. 30, Iss. 4, pp. 1167-1178
Open Access | Times Cited: 30
Are the epigenetic changes predictive of therapeutic efficacy for psychiatric disorders? A translational approach towards novel drug targets
Vincenzo Micale, Martina Di Bartolomeo, Serena Di Martino, et al.
Pharmacology & Therapeutics (2022) Vol. 241, pp. 108279-108279
Closed Access | Times Cited: 30
The Effects of Peripubertal THC Exposure in Neurodevelopmental Rat Models of Psychopathology
Martina Di Bartolomeo, Tibor Štark, Serena Di Martino, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3907-3907
Open Access | Times Cited: 12
Individually tailored dosage regimen of full-spectrum Cannabis extracts for autistic core and comorbid symptoms: a real-life report of multi-symptomatic benefits
Patrícia Soares Silva Montagner, Wesley Medeiros, Leandro Cruz Ramires da Silva, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 11
The marijuana-schizophrenia multifaceted nexus: Connections and conundrums towards neurophysiology
Pukar Khanal, Vishal S. Patil, B. M. Patil, et al.
Computational Biology and Chemistry (2023) Vol. 107, pp. 107957-107957
Closed Access | Times Cited: 11
Prolonged incubation with Δ9-tetrahydrocannabinol but not with cannabidiol induces synaptic alterations and mitochondrial impairment in immature and mature rat organotypic hippocampal slices
Costanza Mazzantini, Lorenzo Curti, Daniele Lana, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 183, pp. 117797-117797
Closed Access
Effects of pharmacological inhibition of fatty acid amide hydrolase on corticosterone release: a systematic review of preclinical studies
Christina F. Pereira, Isabelle Boileau, Stefan Kloiber
Discover Mental Health (2025) Vol. 5, Iss. 1
Open Access
The Development of Cannabinoids as Therapeutic Agents in the United States
Conor H. Murray, Brenda M. Gannon, Peter J. Winsauer, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 5, pp. 915-955
Open Access | Times Cited: 3
Investigating Cannabidiol’s Potential as a Supplementary Treatment for Schizophrenia: A Narrative Review
Jes Sebastian Denis Völker, I. Micluția, Ramona-Cristina Vinași
European Journal of Pharmacology (2024) Vol. 979, pp. 176821-176821
Closed Access | Times Cited: 3
Cannabis, Endocannabinoids and Brain Development: From Embryogenesis to Adolescence
Ricardo J. Rodrigues, Joana M. Marques, Attila Köfalvi
Cells (2024) Vol. 13, Iss. 22, pp. 1875-1875
Open Access | Times Cited: 3
Gut–microbiota–brain axis in the vulnerability to psychosis in adulthood after repeated cannabis exposure during adolescence
Xiayun Wan, Akifumi Eguchi, Youge Qu, et al.
European Archives of Psychiatry and Clinical Neuroscience (2022) Vol. 272, Iss. 7, pp. 1297-1309
Closed Access | Times Cited: 15
Early Blockade of CB1 Receptors Ameliorates Schizophrenia-like Alterations in the Neurodevelopmental MAM Model of Schizophrenia
Tibor Štark, Fabio Arturo Iannotti, Serena Di Martino, et al.
Biomolecules (2022) Vol. 12, Iss. 1, pp. 108-108
Open Access | Times Cited: 12
Neuronal and Astrocytic Morphological Alterations Driven by Prolonged Exposure with Δ9-Tetrahydrocannabinol but Not Cannabidiol
Elisa Landucci, Costanza Mazzantini, Daniele Lana, et al.
Toxics (2022) Vol. 10, Iss. 2, pp. 48-48
Open Access | Times Cited: 12
Prenatal MAM exposure raises kynurenic acid levels in the prefrontal cortex of adult rats
Francesca Frescura, Tibor Štark, Edoardo Tiziani, et al.
Pharmacological Reports (2024) Vol. 76, Iss. 4, pp. 887-894
Closed Access | Times Cited: 2
DNA methylation at cannabinoid type 1 and dopamine D2 receptor genes in saliva samples of psychotic subjects: Is there an effect of Cannabis use?
Martina Di Bartolomeo, Andrea Čerňanová, Veronika Petrušová, et al.
Pharmacological Research (2024) Vol. 208, pp. 107343-107343
Open Access | Times Cited: 2
Unveiling behavioral and molecular neuroadaptations related to the antidepressant action of cannabidiol in the unpredictable chronic mild stress model
María S. García‐Gutiérrez, Daniela Navarro, Amaya Austrich-Olivares, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 6
The Relationship Between Cannabis, Cognition, and Schizophrenia: It’s Complicated
Hakan Kayır, Jessica Ruffolo, Patrick McCunn, et al.
Current topics in behavioral neurosciences (2022), pp. 437-461
Closed Access | Times Cited: 8
Enhancing Endocannabinoid Control of Stress with Cannabidiol
Jeremy D. Henson, Luis Vitetta, Michelle Quezada, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 24, pp. 5852-5852
Open Access | Times Cited: 11
Sex-Dependent Synergism of an Edible THC: CBD Formulation in Reducing Anxiety and Depressive-like Symptoms Following Chronic Stress
Enzo Pérez-Valenzuela, Roger Hudson, Taygun C. Uzuneser, et al.
Current Neuropharmacology (2023) Vol. 22, Iss. 12, pp. 2059-2078
Open Access | Times Cited: 4
Phytocannabinoids in neuromodulation: From omics to epigenetics
Subhadip Banerjee, Debolina Saha, Rohit Sharma, et al.
Journal of Ethnopharmacology (2024) Vol. 330, pp. 118201-118201
Closed Access | Times Cited: 1
Biobehavioral Interactions between Endocannabinoid and Hypothalamicpituitary- adrenal Systems in Psychosis: A Systematic Review
Marco Colizzi, Riccardo Bortoletto, Giulia Antolini, et al.
Current Neuropharmacology (2023) Vol. 22, Iss. 3, pp. 495-520
Open Access | Times Cited: 3
Δ9-Tetrahydrocannabinol does not upregulate an aversive dopamine receptor mechanism in adolescent brain unlike in adults
Marie-Eve Di Raddo, Marija Milenković, Meenalochani Sivasubramanian, et al.
Current Research in Neurobiology (2023) Vol. 5, pp. 100107-100107
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top